22 results on '"Mayer, Erica L."'
Search Results
2. Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes
- Author
-
Lenz, Lauren, Neff, Chris, Solimeno, Cara, Cogan, Elizabeth S., Abramson, Vandana G., Boughey, Judy C., Falkson, Carla, Goetz, Matthew P., Ford, James M., Gradishar, William J., Jankowitz, Rachel C., Kaklamani, Virginia G., Marcom, P. Kelly, Richardson, Andrea L., Storniolo, Anna Maria, Tung, Nadine M., Vinayak, Shaveta, Hodgson, Darren R., Lai, Zhongwu, Dearden, Simon, Hennessy, Bryan T., Mayer, Erica L., Mills, Gordon B., Slavin, Thomas P., Gutin, Alexander, Connolly, Roisin M., Telli, Melinda L., Stearns, Vered, Lanchbury, Jerry S., and Timms, Kirsten M.
- Published
- 2023
- Full Text
- View/download PDF
3. New Developments in Systemic Management for High-Risk Early-Stage Hormone-Receptor-Positive, HER2-Negative Breast Cancer
- Author
-
Brett, Jamie O. and Mayer , Erica L.
- Published
- 2023
- Full Text
- View/download PDF
4. A dynamic portrait of adverse events for breast cancer patients: results from a phase II clinical trial of eribulin in advanced HER2-negative breast cancer
- Author
-
Filho, Otto Metzger, Giobbie-Hurder, Anita, Lin, Nancy U., Faggen, Meredith, Come, Steven, Openshaw, Thomas, Constantine, Michael, Walsh, Jeanna, Freedman, Rachel A., Schneider, Bryan, Burstein, Harold J., and Mayer, Erica L.
- Published
- 2021
- Full Text
- View/download PDF
5. Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance)
- Author
-
Rugo, Hope S, Barry, William T, Moreno-Aspitia, Alvaro, Lyss, Alan P, Cirrincione, Constance, Leung, Eleanor, Mayer, Erica L, Naughton, Michael, Toppmeyer, Deborah, Carey, Lisa A, Perez, Edith A, Hudis, Clifford, and Winer, Eric P
- Subjects
Clinical Research ,Clinical Trials and Supportive Activities ,Cancer ,Breast Cancer ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Adult ,Aged ,Aged ,80 and over ,Albumins ,Antibodies ,Monoclonal ,Humanized ,Antineoplastic Combined Chemotherapy Protocols ,Bevacizumab ,Breast Neoplasms ,Drug Administration Schedule ,Epothilones ,Female ,Humans ,Middle Aged ,Nanoparticles ,Neoplasm Metastasis ,Neoplasm Recurrence ,Local ,Paclitaxel ,Treatment Outcome ,Clinical Sciences ,Oncology and Carcinogenesis ,Oncology & Carcinogenesis - Abstract
PurposeWe compared nab-paclitaxel or ixabepilone once per week to paclitaxel with bevacizumab as first-line therapy for patients with advanced breast cancer (BC) to evaluate progression-free survival (PFS) for nab-paclitaxel or ixabepilone versus paclitaxel.Patients and methodsEligible patients were age ≥ 18 years with chemotherapy-naive advanced BC. Patients were randomly assigned to bevacizumab with paclitaxel 90 mg/m(2) (arm A), nab-paclitaxel 150 mg/m(2) (arm B), or ixabepilone 16 mg/m(2) (arm C), once per week for 3 of 4 weeks. Planned enrollment was 900 patients, which would give 88% power to detect a hazard ratio of 0.73.ResultsIn all, 799 patients were enrolled, and 783 received treatment (97% received bevacizumab). Arm C was closed for futility at the first interim analysis (n = 241), and arm A (n = 267) and arm B (n = 275) were closed for futility at the second interim analysis. Median PFS for paclitaxel was 11 months, ixabepilone was inferior to paclitaxel (PFS, 7.4 months; hazard ratio, 1.59; 95% CI, 1.31 to 1.93; P < .001), and nab-paclitaxel was not superior to paclitaxel (PFS, 9.3 months; hazard ratio, 1.20; 95% CI, 1.00 to 1.45; P = .054). Results were concordant with overall survival; time to treatment failure was significantly shorter in both experimental arms v paclitaxel. Hematologic and nonhematologic toxicity, including peripheral neuropathy, was increased with nab-paclitaxel, with more frequent and earlier dose reductions.ConclusionIn patients with chemotherapy-naive advanced BC, ixabepilone once per week was inferior to paclitaxel, and nab-paclitaxel was not superior with a trend toward inferiority. Toxicity was increased in the experimental arms, particularly for nab-paclitaxel. Paclitaxel once per week remains the preferred palliative chemotherapy in this setting.
- Published
- 2015
6. TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer
- Author
-
Isakoff, Steven J, Mayer, Erica L, He, Lei, Traina, Tiffany A, Carey, Lisa A, Krag, Karen J, Rugo, Hope S, Liu, Minetta C, Stearns, Vered, Come, Steven E, Timms, Kirsten M, Hartman, Anne-Renee, Borger, Darrel R, Finkelstein, Dianne M, Garber, Judy E, Ryan, Paula D, Winer, Eric P, Goss, Paul E, and Ellisen, Leif W
- Subjects
Genetics ,Cancer ,Clinical Research ,Clinical Trials and Supportive Activities ,Breast Cancer ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Good Health and Well Being ,Adult ,Aged ,Antineoplastic Agents ,BRCA1 Protein ,BRCA2 Protein ,Biomarkers ,Tumor ,Carboplatin ,Cisplatin ,Class I Phosphatidylinositol 3-Kinases ,Drug Administration Schedule ,Female ,Gene Expression Profiling ,Gene Expression Regulation ,Neoplastic ,Genomic Instability ,Heterozygote ,Humans ,Loss of Heterozygosity ,Middle Aged ,Mutation ,Neoplasm Staging ,Phosphatidylinositol 3-Kinases ,Treatment Outcome ,Triple Negative Breast Neoplasms ,Clinical Sciences ,Oncology and Carcinogenesis ,Oncology & Carcinogenesis - Abstract
PurposeThe identification of patients with metastatic triple-negative breast cancer (mTNBC) who are expected to benefit from platinum-based chemotherapy is of interest. We conducted a single-arm phase II clinical trial of single-agent platinum for mTNBC with biomarker correlates.Patients and methodsPatients with mTNBC received first- or second-line cisplatin (75 mg/m(2)) or carboplatin (area under the concentration-time curve 6) by physician's choice once every 3 weeks. Coprimary end points were objective response rate (RR) and response prediction by p63/p73 gene expression. Secondary and exploratory end points included toxicity assessment, RR in cisplatin versus carboplatin, and RR in molecularly defined subgroups, including BRCA1/2 mutation carriers.ResultsPatients (N = 86; 69 as first-line therapy) received cisplatin (n = 43) or carboplatin (n = 43). RR was 25.6% (95% CI, 16.8% to 36%) and was numerically higher with cisplatin (32.6%) than with carboplatin (18.7%). RR was 54.5% in patients with germline BRCA1/2 mutations (n = 11). In patients without BRCA1/2 mutations (n = 66), exploratory analyses showed that a BRCA-like genomic instability signature (n = 32) discriminated responding and nonresponding tumors (mean homologous recombination deficiency-loss of heterozygosity/homologous recombination deficiency-large-scale state transitions [HRD-LOH/HRD-LST] scores were 12.68 and 5.11, respectively), whereas predefined analysis by p63/p73 expression status (n = 61), p53 and PIK3CA mutation status (n = 53), or PAM50 gene expression subtype (n = 55) did not. Five of the six long-term responders alive at a median of 4.5 years lacked germline BRCA1/2 mutations, and two of them had increased tumor HRD-LOH/HRD-LST scores.ConclusionPlatinum agents are active in mTNBC, especially in patients with germline BRCA1/2 mutations. A measure of tumor DNA repair function may identify patients without mutations who could benefit from platinum therapy agents. Prospective controlled confirmatory trials are warranted.
- Published
- 2015
7. Taxanes for the treatment of breast cancer during pregnancy: an international cohort study.
- Author
-
Guajardo, Ana S Ferrigno, Vaca-Cartagena, Bryan F, Mayer, Erica L, Bousrih, Chayma, Oluchi, Oke, Saura, Cristina, Peccatori, Fedro, Muñoz-Montaño, Wendy, Cabrera-Garcia, Alvaro, Lambertini, Matteo, Corrales, Luis, Becerril-Gaitan, Andrea, Sella, Tal, Newman, Alexandra Bili, Pistilli, Barbara, Martinez, Ashley, Ortiz, Carolina, Joval-Ramentol, Laia, Scarfone, Giovanna, and Buonomo, Barbara
- Subjects
PREMATURE rupture of fetal membranes ,SMALL for gestational age ,BREAST cancer ,FETAL growth retardation ,TAXANES ,PREGNANCY - Abstract
Introduction The addition of taxanes to anthracycline-based chemotherapy is considered standard of care in the treatment of breast cancer. However, there are insufficient data regarding the safety of taxanes during pregnancy. The aim of this study was to describe the incidence of obstetric and neonatal adverse events associated with the use of taxane-containing chemotherapy regimens for the treatment of breast cancer during pregnancy. Methods This is a multicenter, international cohort study of breast cancer patients treated with taxanes during pregnancy. A descriptive analysis was undertaken to synthetize available data. Results A total of 103 patients were included, most of whom were treated with paclitaxel and anthracyclines given in sequence during gestation (90.1%). The median gestational age at taxane initiation was 28 weeks (range = 12-37 weeks). Grade 3-4 adverse events were reported in 7 of 103 (6.8%) patients. The most common reported obstetric complications were intrauterine growth restriction (n = 8 of 94, 8.5%) and preterm premature rupture of membranes (n = 5 of 94, 5.3%). The live birth rate was 92 of 94 (97.9%), and the median gestational age at delivery was 37 weeks (range = 32-40 weeks). Admission to an intensive care unit was reported in 14 of 88 (15.9%) neonates, and 17 of 70 (24.3%) live births resulted in small for gestational age neonates. Congenital malformations were reported in 2 of 93 (2.2%). Conclusion Obstetric and neonatal outcomes after taxane exposure during pregnancy were generally favorable and did not seem to differ from those reported in the literature with standard anthracycline-based regimens. This study supports the use of taxanes during gestation when clinically indicated. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer
- Author
-
Carey, Lisa A, Rugo, Hope S, Marcom, P Kelly, Mayer, Erica L, Esteva, Francisco J, Ma, Cynthia X, Liu, Minetta C, Storniolo, Anna Maria, Rimawi, Mothaffar F, Forero-Torres, Andres, Wolff, Antonio C, Hobday, Timothy J, Ivanova, Anastasia, Chiu, Wing-Keung, Ferraro, Madlyn, Burrows, Emily, Bernard, Philip S, Hoadley, Katherine A, Perou, Charles M, and Winer, Eric P
- Subjects
Biotechnology ,Genetics ,Breast Cancer ,Clinical Trials and Supportive Activities ,Cancer ,Clinical Research ,Human Genome ,6.2 Cellular and gene therapies ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Adult ,Aged ,Aged ,80 and over ,Antibodies ,Monoclonal ,Antibodies ,Monoclonal ,Humanized ,Antineoplastic Combined Chemotherapy Protocols ,Biomarkers ,Tumor ,Breast Neoplasms ,Carboplatin ,Cetuximab ,Disease Progression ,Female ,Humans ,Middle Aged ,Neoplasm Staging ,Receptor ,ErbB-2 ,Receptors ,Estrogen ,Receptors ,Progesterone ,Signal Transduction ,Survival Analysis ,Treatment Outcome ,Receptor ,erbB-2 ,Clinical Sciences ,Oncology and Carcinogenesis ,Oncology & Carcinogenesis - Abstract
PurposeEpidermal growth factor receptor (EGFR) is a targetable receptor frequently overexpressed in basal-like breast cancer, which comprises most triple-negative breast cancers (TNBCs), the only subtype without established targeted therapy.Patients and methodsIn this randomized phase II trial, patients with metastatic TNBC received anti-EGFR antibody cetuximab (400 mg/m(2) load then 250 mg/m(2) per week intravenously [IV]) alone, with carboplatin (area under the curve of 2, once per week IV) added after progression or as concomitant therapy from the beginning. Response rate (RR) was the primary end point; others included time to progression (TTP), overall survival (OS), and toxicity. Embedded correlative studies included molecular subtyping on archival tissue. Fresh tumor tissue before and after 7 to 14 days of therapy was used for microarray analyses exploring EGFR pathway activity and inhibition.ResultsIn 102 patients with TNBC, RRs were 6% (two of 31) to cetuximab and 16% (four of 25) to cetuximab plus carboplatin after progression. RR to those treated from the beginning with cetuximab plus carboplatin was 17% (12 of 71); 31% of patients responded or had prolonged disease stabilization. The cetuximab plus carboplatin regimen was well tolerated, but both TTP and OS were short at 2.1 months (95% CI, 1.8 to 5.5 months) and 10.4 months (95% CI, 7.7 to 13.1 months), respectively. Of 73 patients with archival tissue for analysis, 74% had basal-like molecular subtype. Sixteen patients had tumor biopsies before and 1 week after therapy; genomic patterns of the EGFR pathway showed activation in 13 and inhibition by therapy in five.ConclusionDespite strong preclinical data, combination cetuximab plus carboplatin in metastatic TNBC produced responses in fewer than 20% of patients. EGFR pathway analysis showed that most TNBCs involved activation. However, cetuximab blocked expression of the EGFR pathway in only a minority, suggesting that most had alternate mechanisms for pathway activation.
- Published
- 2012
9. Staging Workup in Pregnant Cancer Patients
- Author
-
O’Neill, Ailbhe C., DiPiro, Pamela J., Mayer, Erica L., and Azim Jr, Hatem A., editor
- Published
- 2016
- Full Text
- View/download PDF
10. Targeting Breast Cancer with CDK Inhibitors
- Author
-
Mayer, Erica L.
- Published
- 2015
- Full Text
- View/download PDF
11. Contemporary multidisciplinary treatment of pregnancy-associated breast cancer
- Author
-
Meisel, Jane L, Economy, Katherine E, Calvillo, Katherina Zabicki, Schapira, Lydia, Tung, Nadine M, Gelber, Shari, Kereakoglow, Sandra, Partridge, Ann H, and Mayer, Erica L
- Published
- 2013
- Full Text
- View/download PDF
12. Prospective clinical experience with research biopsies in breast cancer patients
- Author
-
Vaz-Luis, Ines, Zeghibe, Catherine A., Frank, Elizabeth S., Sohl, Jessica, Washington, Kimberly E., Silverman, Stuart G., Fonte, Joseph M., Mayer, Erica L., Overmoyer, Beth A., Richardson, Andrea L., Krop, Ian E., Winer, Eric P., and Lin, Nancy U.
- Published
- 2013
- Full Text
- View/download PDF
13. A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases
- Author
-
Lin, Nancy U., Freedman, Rachel A., Ramakrishna, Naren, Younger, Jerry, Storniolo, Anna Maria, Bellon, Jennifer R., Come, Steven E., Gelman, Rebecca S., Harris, Gordon J., Henderson, Mark A., MacDonald, Shannon M., Mahadevan, Anand, Eisenberg, Emily, Ligibel, Jennifer A., Mayer, Erica L., Moy, Beverly, Eichler, April F., and Winer, Eric P.
- Published
- 2013
- Full Text
- View/download PDF
14. What's the reality for CDK4/6 inhibitors: Clinical trials or real‐world evidence?
- Author
-
Trapani, Dario and Mayer, Erica L.
- Subjects
- *
CYCLIN-dependent kinase inhibitors , *CLINICAL trials , *BREAST cancer , *CYCLIN-dependent kinases - Abstract
Clinical trials and real‐world evidence (RWE) present conflicting results on the benefit of cyclin‐dependent kinase 4 and 6 inhibitors for patients with advanced hormone receptor–positive and human epidermal growth factor receptor‐2 overexpressing breast cancer. How can RWE be interpreted and used to help guide clinical decisions? [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
15. Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomics
- Author
-
Mayer, Erica L., Isakoff, Steven J., Klement, Giannoula, Downing, Sean R., Chen, Wendy Y., Hannagan, Keri, Gelman, Rebecca, Winer, Eric P., and Burstein, Harold J.
- Published
- 2012
- Full Text
- View/download PDF
16. Anti-Angiogenic Strategies in Breast Cancer: An Update
- Author
-
Gropper, Adrienne B. and Mayer, Erica L.
- Published
- 2010
- Full Text
- View/download PDF
17. Birthweight and Chemotherapy Exposure in Women Diagnosed with Breast Cancer during Pregnancy.
- Author
-
Freret, Taylor S., Exman, Pedro, Mayer, Erica L., Little, Sarah E., and Economy, Katherine E.
- Subjects
ACADEMIC medical centers ,CANCER chemotherapy ,RETROSPECTIVE studies ,ACQUISITION of data ,REGRESSION analysis ,FISHER exact test ,PRENATAL exposure delayed effects ,SEX distribution ,TREATMENT effectiveness ,BIRTH weight ,MEDICAL records ,BREAST tumors ,SMALL for gestational age ,LONGITUDINAL method ,PREGNANCY - Abstract
Objective Breast cancer is one of the most frequently diagnosed cancers in pregnancy and is commonly treated with chemotherapy. To date, studies examining effects of chemotherapy during pregnancy on fetal growth have yielded conflicting results, and most are limited by small sample sizes or are nonspecific with respect to cytotoxic regimen or type of cancer treated. We sought to evaluate the effect of chemotherapy for breast cancer in pregnancy on birthweight and small for gestational age infants. Study Design This is a retrospective cohort study of 74 women diagnosed with pathologically confirmed breast cancer during pregnancy between 1997 and 2018 at one of three academic medical centers, who had a singleton birth with known birthweight. Forty-nine received chemotherapy and 25 did not receive chemotherapy. Linear regression modeling was used to compare birthweight (by gestational age and sex-specific z -score) by chemotherapy exposure. Subanalyses of specific chemotherapy regimen and duration of chemotherapy exposure were also performed. Placental, neonatal, and maternal outcomes were also analyzed by chemotherapy exposure. Results In the adjusted model, chemotherapy exposure was associated with lower birthweight (Δ z -score = −0.49, p = 0.03), but similar rates of small for gestational age (defined as birthweight <10th percentile for gestational age) infants (8.2 vs. 8.0%, p = 1.0; Fisher's exact test). Each additional week of chemotherapy (Δ z -score = −0.05, p = 0.03) was associated with decreased birthweight, although no association was found with specific chemotherapy regimen. Chemotherapy exposure was associated with lower median placental weight percentile by gestational age (9th vs. 75th, p < 0.05). Secondary maternal outcomes were similar between the group that did and did not receive chemotherapy. Conclusion Chemotherapy for breast cancer in pregnancy in this cohort is associated with lower birthweight but no difference in the rate of small for gestational age infants. Key Points Chemotherapy for breast cancer in pregnancy is associated with decreased birthweight but similar rates of small for gestational age infants. Birthweight did not differ according to chemotherapy regimen. There is no difference in the rate of small for gestational age infants. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
18. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study.
- Author
-
Mayer, Erica L, Dueck, Amylou C, Martin, Miguel, Rubovszky, Gabor, Burstein, Harold J, Bellet-Ezquerra, Meritxell, Miller, Kathy D, Zdenkowski, Nicholas, Winer, Eric P, Pfeiler, Georg, Goetz, Matthew, Ruiz-Borrego, Manuel, Anderson, Daniel, Nowecki, Zbigniew, Loibl, Sibylle, Moulder, Stacy, Ring, Alistair, Fitzal, Florian, Traina, Tiffany, and Chan, Arlene
- Subjects
- *
HORMONE receptor positive breast cancer , *HORMONE therapy , *BREAST cancer , *METASTATIC breast cancer , *PROGRESSION-free survival , *LUTEINIZING hormone , *PYRIDINE , *PROTEINS , *RESEARCH , *HETEROCYCLIC compounds , *RESEARCH methodology , *ANTINEOPLASTIC agents , *PROGNOSIS , *CELL receptors , *EVALUATION research , *MEDICAL cooperation , *COMPARATIVE studies , *AROMATASE inhibitors , *TAMOXIFEN , *BREAST tumors , *PROPORTIONAL hazards models - Abstract
Background: Palbociclib added to endocrine therapy improves progression-free survival in hormone-receptor-positive, HER2-negative, metastatic breast cancer. The PALLAS trial aimed to investigate whether the addition of 2 years of palbociclib to adjuvant endocrine therapy improves invasive disease-free survival over endocrine therapy alone in patients with hormone-receptor-positive, HER2-negative, early-stage breast cancer.Methods: PALLAS is an ongoing multicentre, open-label, randomised, phase 3 study that enrolled patients at 406 cancer centres in 21 countries worldwide with stage II-III histologically confirmed hormone-receptor-positive, HER2-negative breast cancer, within 12 months of initial diagnosis. Eligible patients were aged 18 years or older with an Eastern Cooperative Oncology Group performance score of 0 or 1. Patients were randomly assigned (1:1) in permuted blocks of random size (4 or 6), stratified by anatomic stage, previous chemotherapy, age, and geographical region, by use of central telephone-based and web-based interactive response technology, to receive either 2 years of palbociclib (125 mg orally once daily on days 1-21 of a 28-day cycle) with ongoing standard provider or patient-choice adjuvant endocrine therapy (tamoxifen or aromatase inhibitor, with or without concurrent luteinising hormone-releasing hormone agonist), or endocrine therapy alone, without masking. The primary endpoint of the study was invasive disease-free survival in the intention-to-treat population. Safety was assessed in all randomly assigned patients who started palbociclib or endocrine therapy. This report presents results from the second pre-planned interim analysis triggered on Jan 9, 2020, when 67% of the total number of expected invasive disease-free survival events had been observed. The trial is registered with ClinicalTrials.gov (NCT02513394) and EudraCT (2014-005181-30).Findings: Between Sept 1, 2015, and Nov 30, 2018, 5760 patients were randomly assigned to receive palbociclib plus endocrine therapy (n=2883) or endocrine therapy alone (n=2877). At the time of the planned second interim analysis, at a median follow-up of 23·7 months (IQR 16·9-29·2), 170 of 2883 patients assigned to palbociclib plus endocrine therapy and 181 of 2877 assigned to endocrine therapy alone had invasive disease-free survival events. 3-year invasive disease-free survival was 88·2% (95% CI 85·2-90·6) for palbociclib plus endocrine therapy and 88·5% (85·8-90·7) for endocrine therapy alone (hazard ratio 0·93 [95% CI 0·76-1·15]; log-rank p=0·51). As the test statistic comparing invasive disease-free survival between groups crossed the prespecified futility boundary, the independent data monitoring committee recommended discontinuation of palbociclib in patients still receiving palbociclib and endocrine therapy. The most common grade 3-4 adverse events were neutropenia (1742 [61·3%] of 2840 patients on palbociclib and endocrine therapy vs 11 [0·3%] of 2903 on endocrine therapy alone), leucopenia (857 [30·2%] vs three [0·1%]), and fatigue (60 [2·1%] vs ten [0·3%]). Serious adverse events occurred in 351 (12·4%) of 2840 patients on palbociclib plus endocrine therapy versus 220 (7·6%) of 2903 patients on endocrine therapy alone. There were no treatment-related deaths.Interpretation: At the planned second interim analysis, addition of 2 years of adjuvant palbociclib to adjuvant endocrine therapy did not improve invasive disease-free survival compared with adjuvant endocrine therapy alone. On the basis of these findings, this regimen cannot be recommended in the adjuvant setting. Long-term follow-up of the PALLAS population and correlative studies are ongoing.Funding: Pfizer. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
19. Contemporary management of breast cancer during pregnancy and subsequent lactation in a multicenter cohort of young women with breast cancer.
- Author
-
Lee, Guek Eng, Rosenberg, Shoshana M, Mayer, Erica L, Borges, Virginia, Meyer, Meghan E, Schapira, Lidia, Come, Steven E, and Partridge, Ann H
- Subjects
BREAST tumor diagnosis ,BREAST tumor treatment ,ABORTION ,BREASTFEEDING ,CANCER invasiveness ,CELL receptors ,CHILDBIRTH ,COMBINED modality therapy ,DELIVERY (Obstetrics) ,GESTATIONAL age ,LACTATION ,LONGITUDINAL method ,MEDICAL cooperation ,MEDICAL records ,ONCOGENES ,FIRST trimester of pregnancy ,SECOND trimester of pregnancy ,THIRD trimester of pregnancy ,RESEARCH ,SURVEYS ,WOMEN'S health ,LUMPECTOMY ,TREATMENT effectiveness ,ACQUISITION of data methodology ,PREGNANCY - Abstract
The incidence of breast cancer diagnosed during pregnancy is increasing. We sought to characterize patient, treatment, pregnancy and lactation factors among young women with newly diagnosed breast cancer during pregnancy in a prospective cohort study. We identified all women who were pregnant when diagnosed with invasive breast cancer among those enrolled in the Young Women's Breast Cancer Study (NCT01468246), and collected details on pregnancy, birth and lactation from surveys, and treatment information medical record review. Of 1302 enrolled participants, 976 women with invasive breast cancer completed full baseline surveys, among whom 39 (4.0%) patients reported being pregnant at diagnosis. Median age at diagnosis was 34 years (range: 25‐40), with stage distribution: I, 28%; II, 44%; III, 23%; and IV, 5%. 74% of patients (29/39) had grade 3 tumors, 59% (23/39) ER‐positive, and 31% (12/39) HER2‐positive disease. 23 (59%) had surgery during pregnancy, 4 (17%) during the first trimester. Among the women who had surgery during pregnancy, 61% (14/23) underwent lumpectomy, 35% (8/23) unilateral, and 4% (1/23) bilateral mastectomy. All patients who had chemotherapy (51%, 20/39) received it in second and third trimesters, and had ACx4. There were 31 live births, 2 spontaneous, and 5 therapeutic abortions. Among live births, 16 (41%) were before 37 weeks of gestation. Three women reported breastfeeding. Within 6 months after delivery, comprehensive staging in 13 patients showed upstaging in four patients. In a contemporary cohort of young women with breast cancer, pregnancy at diagnosis is relatively uncommon. Treatment during pregnancy can generally be consistent with standard surgical and chemotherapy approaches, with attention to timing of therapies. Longer‐term outcomes including effects of some timing issues including delayed use of anti‐HER2 therapy on patient outcomes warrant further research. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
20. 'ADVANCE' (a pilot trial) ADjuVANt chemotherapy in the elderly: Developing and evaluating lower-toxicity chemotherapy options for older patients with breast cancer.
- Author
-
Freedman, Rachel A., Li, Tianyu, Sedrak, Mina S., Hopkins, Judith O., Tayob, Nabihah, Faggen, Meredith G., Sinclair, Natalie F., Chen, Wendy Y., Parsons, Heather A., Mayer, Erica L., Lange, Paulina B., Basta, Ameer S., Perilla-Glen, Adriana, Lederman, Ruth I., Wong, Andrew, Tiwari, Abhay, McAllister, Sandra S., Mittendorf, Elizabeth A., Miller, Peter G., and Gibson, Christopher J.
- Abstract
Older adults with breast cancer receiving neo/adjuvant chemotherapy are at high risk for poor outcomes and are underrepresented in clinical trials. The ADVANCE (AD ju VAN t C hemotherapy in the E lderly) trial evaluated the feasibility of two neo/adjuvant chemotherapy regimens in parallel-enrolling cohorts of older patients with human epidermal growth factor receptor 2-negative breast cancer: cohort 1—triple-negative; cohort 2—hormone receptor-positive. Adults age ≥ 70 years with stage I-III breast cancer warranting neo/adjuvant chemotherapy were enrolled. Cohort 1 received weekly carboplatin (area under the curve 2) and weekly paclitaxel 80 mg/m
2 for twelve weeks; cohort 2 received weekly paclitaxel 80 mg/m2 plus every-three-weekly cyclophosphamide 600 mg/m2 over twelve weeks. The primary study endpoint was feasibility, defined as ≥80% of patients receiving ≥80% of intended weeks/doses of therapy. All dose modifications were applied per clinician discretion. Forty women (n = 20 per cohort) were enrolled from March 25, 2019 through August 3, 2020 from three centers; 45% and 35% of patients in cohorts 1 and 2 were age > 75, respectively. Neither cohort achieved targeted thresholds for feasibility. In cohort 1, eight (40.0%) met feasibility (95% confidence interval [CI] = 19.1–63.9%), while ten (50.0%) met feasibility in cohort 2 (95% CI = 27.2–72.8). Neutropenia was the most common grade 3–4 toxicity (cohort 1—65%, cohort 2—55%). In cohort 1, 80% and 85% required ≥1 dose holds of carboplatin and/or paclitaxel, respectively. In cohort 2, 10% required dose hold(s) for cyclophosphamide and/or 65% for paclitaxel. In this pragmatic pilot examining chemotherapy regimens in older adults with breast cancer, neither regimen met target goals for feasibility. Developing efficacious and tolerable regimens for older patients with breast cancer who need chemotherapy remains an important goal. ClinicalTrials.gov Identifier: NCT03858322. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
21. Cyclin dependent kinase 4/6 inhibitors in early breast cancer: what is the role of Ki-67?
- Author
-
Antonarelli, Gabriele, Valenza, Carmine, Mayer, Erica L, Loibl, Sibylle, and Curigliano, Giuseppe
- Subjects
- *
KINASE inhibitors , *BREAST cancer , *CYCLINS , *KI-67 antigen , *CYCLIN-dependent kinases - Published
- 2022
- Full Text
- View/download PDF
22. Radiation Therapy and Cardiotoxicity
- Author
-
Palta, Manisha, Lee, Chang-Lung, Yusuf, Syed Wamique, Kirsch, David G., Kimmick, Gretchen G., editor, Lenihan, Daniel J., editor, Sawyer, Douglas B., editor, Mayer, Erica L., editor, and Hershman, Dawn L., editor
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.